No connection

Search Results

TNON vs XWEL

TNON
Tenon Medical, Inc.
BEARISH
Price
$0.80
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
90%
XWEL
XWELL, Inc.
BEARISH
Price
$1.14
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
TNON
--
XWEL
--
Forward P/E
TNON
-1.28
XWEL
-0.43
P/B Ratio
TNON
4.41
XWEL
-1.04
P/S Ratio
TNON
2.29
XWEL
0.31
EV/EBITDA
TNON
-0.72
XWEL
-3.37

Profitability

Gross Margin
TNON
59.79%
XWEL
25.7%
Operating Margin
TNON
-193.52%
XWEL
-45.07%
Profit Margin
TNON
0.0%
XWEL
-58.17%
ROE
TNON
-228.06%
XWEL
--
ROA
TNON
-72.88%
XWEL
-31.98%

Growth

Revenue Growth
TNON
92.3%
XWEL
-4.2%
Earnings Growth
TNON
--
XWEL
--

Financial Health

Debt/Equity
TNON
0.03
XWEL
--
Current Ratio
TNON
2.11
XWEL
0.46
Quick Ratio
TNON
1.7
XWEL
0.33

Dividends

Dividend Yield
TNON
--
XWEL
--
Payout Ratio
TNON
0.0%
XWEL
0.0%

AI Verdict

TNON BEARISH

TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.

Strengths
Strong YoY revenue growth of 92.30%
High gross margin of 59.79% indicating product value
Very low leverage with a Debt/Equity ratio of 0.03
Risks
Critical financial health as evidenced by Piotroski F-Score of 1/9
Severe operational losses with an operating margin of -193.52%
Extreme equity erosion indicated by ROE of -228.06%
XWEL BEARISH

XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.

Strengths
Low Price-to-Sales ratio (0.31) suggests the market has already priced in significant failure
Recent quarterly EPS surprises have been positive (beating negative estimates)
Short-term 1-year price performance shows speculative interest (+48%)
Risks
Extreme bankruptcy risk indicated by Piotroski F-Score of 1/9
Negative equity (P/B -1.04) indicates liabilities exceed assets
Severe liquidity shortage with a Current Ratio well below 1.0 (0.46)

Compare Another Pair

TNON vs XWEL: Head-to-Head Comparison

This page compares Tenon Medical, Inc. (TNON) and XWELL, Inc. (XWEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile